Key references: Glucocorticoid-induced osteoporosis

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2017;69(8):1521–37. https://www.ncbi.nlm.nih.gov/pubmed/28585373
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12(1):43. https://www.ncbi.nlm.nih.gov/pubmed/28425085
Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 2018;6(6):445–54. https://www.ncbi.nlm.nih.gov/pubmed/29631782
Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis and the prevention of fragility fractures [SIGN 142]. Edinburgh: SIGN; 2015. https://www.sign.ac.uk/sign-142-management-of-osteoporosis-and-the-prevention-of-fragility-fractures.html